We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
+4.78%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$484M
AUM Growth
+$55.1M
Cap. Flow
+$73.1M
Cap. Flow %
15.11%
Top 10 Hldgs %
57.22%
Holding
53
New
11
Increased
11
Reduced
16
Closed
15

Top Buys

Rank Stock Value
1
PRCT icon
Procept Biorobotics
PRCT
+$43.2M
2
JANX icon
Janux Therapeutics
JANX
+$35.9M
3
NKTR icon
Nektar Therapeutics
NKTR
+$31M
4
VEEV icon
Veeva Systems
VEEV
+$23.9M
5
PHR icon
Phreesia
PHR
+$20.2M

Top Sells

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$21.8M
2
BBIO icon
BridgeBio Pharma
BBIO
+$15.4M
3
ROIV icon
Roivant Sciences
ROIV
+$14M
4
DXCM icon
DexCom
DXCM
+$13.1M
5
IMVT icon
Immunovant
IMVT
+$10.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.58%
2 Industrials 0.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRCT icon
1
Procept Biorobotics
PRCT
$1.19B
$43.4M 8.97%
1,380,000
+1,303,009
+1,692% +$43.2M
LKFT
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$35.1M 7.26%
1,074,112
-75,888
-7% -$2.45M
JANX icon
3
Janux Therapeutics
JANX
$1.1B
$33M 6.82%
2,392,523
+1,527,173
+176% +$35.9M
ADCT icon
4
ADC Therapeutics
ADCT
$146M
$29.9M 6.18%
8,477,338
+1,005,035
+13% +$4.08M
KURA icon
5
Kura Oncology
KURA
$1.13B
$26.3M 5.43%
2,529,600
-228,916
-8% -$2.4M
MGTX icon
6
MeiraGTx Holdings
MGTX
$1.33B
$25.5M 5.27%
3,209,788
-879,721
-22% -$7.31M
NKTR icon
7
Nektar Therapeutics
NKTR
$2.48B
$23.4M 4.85%
+554,633
New +$31M
VEEV icon
8
Veeva Systems
VEEV
$44.8B
$20.1M 4.16%
+90,133
New +$23.9M
ICLR icon
9
Icon
ICLR
$13.1B
$20M 4.14%
110,000
+500
+0.5% +$89K
BSX icon
10
Boston Scientific
BSX
$67.9B
$20M 4.14%
210,000
+133,900
+176% +$13.1M
CON
11
Concentra Group Holdings
CON
$4.37B
$17.5M 3.62%
891,030
+281,030
+46% +$5.62M
PHR icon
12
Phreesia
PHR
$751M
$16.5M 3.42%
+977,152
New +$20.2M
FOLD
13
DELISTED
Amicus Therapeutics
FOLD
$16.4M 3.38%
1,150,000
-559,533
-33% -$5.5M
SEM
14
DELISTED
Select Medical
SEM
$15.4M 3.18%
1,035,086
+160,171
+18% +$2.26M
SNDX icon
15
Syndax Pharmaceuticals
SNDX
$1.74B
$14M 2.89%
665,000
-338,400
-34% -$5.9M
ZYME icon
16
Zymeworks
ZYME
$2.02B
$14M 2.89%
530,393
-219,218
-29% -$4.78M
ROIV icon
17
Roivant Sciences
ROIV
$25.1B
$13.6M 2.81%
627,162
-708,338
-53% -$14M
CRNX icon
18
Crinetics Pharmaceuticals
CRNX
$9B
$12.2M 2.53%
262,904
-65,780
-20% -$2.93M
AVTR icon
19
Avantor
AVTR
$9.86B
$10.3M 2.13%
+898,499
New +$11.1M
STTK icon
20
Shattuck Labs
STTK
$707M
$8.69M 1.8%
2,381,502
-3,069,693
-56% -$7.32M
LH icon
21
Labcorp
LH
$27.2B
$8.66M 1.79%
+34,532
New +$9.17M
WGS icon
22
GeneDx Holdings
WGS
$2.57B
$7.15M 1.48%
+55,000
New +$7.55M
ALNY icon
23
Alnylam Pharmaceuticals
ALNY
$31.7B
$6.8M 1.41%
+17,109
New +$7.57M
IMVT icon
24
Immunovant
IMVT
$8.51B
$6.19M 1.28%
243,404
-455,068
-65% -$10.1M
CRBP icon
25
Corbus Pharmaceuticals
CRBP
$211M
$5.57M 1.15%
683,872
+340,472
+99% +$4.2M
1
2 3

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q4 2025 Portfolio in Review

As of Q4 2025, Prosight Management held 53 positions worth $484M, up 13% from $429M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Prosight Management deployed $73.1M of net new capital in Q4 2025, opening 11 new positions and adding to 11 existing holdings. Its largest new stake was Nektar Therapeutics: 554,633 shares worth $23.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was BridgeBio Pharma, an estimated $15.4M trimmed.

  • Prosight Management's largest Q4 2025 buy was Nektar Therapeutics: 554,633 shares worth $23.4M.
  • Prosight Management added most to Procept Biorobotics in Q4 2025, an estimated $43.2M increase.
  • Prosight Management's biggest Q4 2025 reduction was BridgeBio Pharma, cutting an estimated $15.4M.
  • Prosight Management fully exited Intuitive Surgical in Q4 2025, selling an estimated $21.8M.
  • Prosight Management's ten largest holdings make up 57% of its $484M portfolio in Q4 2025.
  • Prosight Management opened 11 new positions and closed 15 in Q4 2025.
  • Prosight Management's portfolio value rose 13% quarter-over-quarter to $484M.

Based on Prosight Management's 13F filing for Q4 2025, filed 13 Feb 2026.